Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has scheduled its second quarter 2025 financial results announcement for August 6, 2025 after market close.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast and presentation materials through the "Events" section of Arcutis' website, with an archived replay available afterward on their investor website.
Arcutis Biotherapeutics (Nasdaq: ARQT), un'azienda biofarmaceutica in fase commerciale specializzata in innovazioni immuno-dermatologiche, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 6 agosto 2025 dopo la chiusura del mercato.
La società terrà una conference call e una webcast alle 16:30 ET dello stesso giorno. Gli investitori potranno accedere alla diretta streaming e ai materiali della presentazione tramite la sezione "Eventi" del sito web di Arcutis, con una replica archiviata disponibile successivamente sul sito dedicato agli investitori.
Arcutis Biotherapeutics (Nasdaq: ARQT), una compañía biofarmacéutica en etapa comercial especializada en innovaciones inmunodermatológicas, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 6 de agosto de 2025 después del cierre del mercado.
La empresa realizará una llamada conferencia y una transmisión en vivo a las 4:30 p.m. ET ese mismo día. Los inversores podrán acceder a la transmisión en vivo y a los materiales de la presentación a través de la sección "Eventos" del sitio web de Arcutis, con una repetición archivada disponible posteriormente en su sitio web para inversores.
Arcutis Biotherapeutics (나스닥: ARQT)는 면역 피부학 혁신에 특화된 상업 단계의 바이오제약 회사로, 2025년 2분기 재무 실적 발표를 2025년 8월 6일 장 마감 후에 예정하고 있습니다.
회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 투자자들은 Arcutis 웹사이트의 "이벤트" 섹션을 통해 생중계와 발표 자료에 접속할 수 있으며, 이후 투자자 웹사이트에서 녹화된 다시보기를 이용할 수 있습니다.
Arcutis Biotherapeutics (Nasdaq : ARQT), une entreprise biopharmaceutique en phase commerciale spécialisée dans les innovations en immunodermatologie, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 6 août 2025 après la clôture du marché.
L'entreprise organisera une conférence téléphonique et une webdiffusion à 16h30 ET le même jour. Les investisseurs pourront accéder à la diffusion en direct et aux documents de présentation via la section « Événements » du site web d'Arcutis, avec une rediffusion archivée disponible ensuite sur leur site dédié aux investisseurs.
Arcutis Biotherapeutics (Nasdaq: ARQT), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Innovationen im Bereich Immun-Dermatologie spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 6. August 2025 nach Börsenschluss geplant.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und eine Webcast veranstalten. Investoren können den Live-Webcast und die Präsentationsmaterialien über den Bereich "Events" auf der Website von Arcutis abrufen; eine archivierte Wiedergabe steht anschließend auf der Investorenseite zur Verfügung.
- None.
- None.
WESTLAKE VILLAGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET.
A live webcast of the call and the presentation materials will be available on the “Events” section of the Company’s website. An archived replay of the webcast will be available on the Arcutis investor website following the conference call.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to invent differentiated therapies against biologically validated targets, and has produced a robust pipeline with multiple follow-on clinical programs for a range of inflammatory dermatological conditions including atopic dermatitis and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
FAQ
When will Arcutis (ARQT) report Q2 2025 earnings?
What time is the Arcutis (ARQT) Q2 2025 earnings call?
How can I access Arcutis (ARQT) Q2 2025 earnings webcast?
What does Arcutis Biotherapeutics (ARQT) specialize in?
